Comparative Pharmacology
Head-to-head clinical analysis: CALAN SR versus TARKA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN SR versus TARKA.
CALAN SR vs TARKA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Combination of trandolapril (angiotensin-converting enzyme inhibitor) and verapamil (calcium channel blocker). Trandolapril inhibits ACE, reducing angiotensin II production, leading to vasodilation and decreased aldosterone secretion. Verapamil blocks L-type calcium channels, causing coronary and peripheral vasodilation, and negative chronotropic/inotropic effects.
Oral: 180–240 mg once daily; maximum 480 mg/day.
Tarka (trandolapril/verapamil) is available as fixed-dose combinations: 1 mg/180 mg, 2 mg/180 mg, 2 mg/240 mg, 4 mg/240 mg. For hypertension, initial dose is 1 mg/180 mg orally once daily; titrate based on blood pressure response, maximum dose 8 mg/480 mg per day.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
Trandolaprilat terminal t1/2 16–24 h (prolonged in renal impairment, e.g., CrCl <30 mL/min ~36 h); verapamil t1/2 6–12 h (active metabolite norverapamil t1/2 ~12 h)
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Renal: trandolaprilat 33% (unchanged 13%), trandolapril 10%; fecal: 66% (trandolaprilat 21%, trandolapril 33%); verapamil: renal 70% (16% unchanged), fecal 16%
Category C
Category C
Calcium Channel Blocker
ACE Inhibitor + Calcium Channel Blocker